Docosahexaenoic acid

VANCOUVER, British Columbia--( BUSINESS WIRE )-- Lobe Sciences, Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) , a biopharmaceutical company focused on developing products to treat diseases with unmet medical needs, today announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma, Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate. Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera. Dr. Sancilio, Chairman and CEO of Lobe Sciences said, “At present, Lobe Sciences has a complex corporate structure. By establishing Alera Pharma, we are simplifying the operations of the Company into just three entities. Lobe Sciences, Ltd will provide common services to the two operating subsidiaries - Alera and Altemia, LLC. The creation of two separate operating companies will allow each entity to create value within their respective therapeutic areas; neurology and hematology.” The Company also announces the receipt from the US PTO of a Notice of Allowance for its U.S. Patent Application Serial No. 18/411,576. About Lobe Sciences Ltd. Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia ® , a medical food designed to meet the needs of sickle cell patients globally. Cautionary Statement Regarding "Forward-Looking" Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the composition of the management team of Alera and the ownership of Lobe Sciences Australia Pty Ltd., are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the management team of Alera will be appointed as currently expected and that Lobe Sciences Australia Pty Ltd. will become a subsidiary of Alera as currently anticipated. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the management team of Alera will be appointed differently as currently expected and that Lobe Sciences Australia Pty Ltd. will not become a subsidiary of Alera as currently anticipated. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

琳琅满目的零食越来越多，家长们也总担心自己的孩子吃太多不健康的零食，比如一些高糖、高油、高盐、高人工添加剂的糖果、巧克力、饼干、薯片、面包等等。但是，我们往往忽视了一个简单却重要的事实：孩子们，甚至许多成人，天生就是喜欢吃零食的。 那么，吃零食是个坏习惯吗？答案是不一定。其实，享受零食本身并不一定会导致体重上升或带来健康隐患。在合适的时间适量地吃点健康零食，不仅可以帮助我们更好地控制饥饿感，甚至还能弥补一些膳食营养不足的问题。关键在于我们怎样选择零食，以及零食的摄入量。 既然如此，为什么我们不为孩子或者自己选择一种既美味又营养的健康零食呢？ 华森制药严品森活系列大健康营养食品——DHA藻油软糖，特添藻油DHA（二十二碳六烯酸），好吃又营养，随时补充儿童眼脑发育至关重要但膳食易摄入不足的Omega-3脂肪酸。 为什么选择华森制药严品森活DHA藻油软糖？ 1.易吸收的藻油DHA：从天然藻类中提取的DHA，比起鱼油DHA，藻油DHA更纯净，降低了海洋污染的风险，更易吸收、更适合儿童食用。 2.纯果汁无添加：在味道和颜色上，我们坚持不使用任何人工添加剂，0添加香精、色素、防腐剂、明胶，保证软糖的成分纯净，安全可靠，让孩子们在享受美味的同时，也能摄入到最自然、最健康的营养。 3.健康与美味的完美结合：零食光健康没用，孩子们更喜欢好吃的零食。因此，我们在保证DHA藻油软糖配方纯净、健康的同时，重点关注了口味的调和，确保健康与美味兼具，让孩子们爱吃。 4.牙齿友好：选用麦芽糖醇代替蔗糖，麦芽糖醇在口腔中不易被转化为酸类物质，降低了孩子出现龋齿的风险。 作为家长，我们都希望给孩子们最好的。既然孩子们本来就要吃零食，为什么不选择DHA藻油软糖这类既美味又富含营养的零食呢？既能满足孩子对零食的天然喜好，又能确保他们摄取到的是营养而不仅仅是热量。 选择华森制药严品森活DHA藻油软糖，用孩子喜欢的方式呵护他们成长。